A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have ...

KRAS G12C inhibitors like sotorasib (Lumakras) and adagrasib (Krazati) have been effective for some patients whose cancers harbor this mutation, but many patients' cancers are resistant to therapy ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C inhibitors, ...

BridgeBio Oncology aims to drug KRAS G12C in both the “on” and “off” states with a drug codenamed BBO-8520. A Phase 1 study is testing this drug in patients with non-small cell lung cancer.

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

The findings, published in Science Advances, could have implications for patients with certain cancers that have KRAS-G12C mutations after resistance to drug therapy develops. "By overcoming ...

Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows ...

Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...

"2024 is a transforatmive year for Jacobio. We have submitted a New Drug Application (NDA) for the KRAS G12C inhibitor glecirasib and have licensed out the China rights of glecirasib and the SHP2 ...